Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]
Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ:AMEX Investor Relations:
ir.citiuspharma.com
Company Research
Source: Yahoo! Finance
Citius Pharmaceuticals Inc. (NASDAQ: CTXR ) is one of the stocks that should double in 3 years . On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following the December 2025 commercial launch of LYMPHIR. For FQ1 2026, the company reported $3.9 million in consolidated revenue, reflecting initial sales through a nationwide network of specialty distributors. This was achieved via Citius Pharma's majority-owned subsidiary, Citius Oncology, Inc., which introduced the targeted immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma. The launch of LYMPHIR is being supported by an AI-enabled commercial platform designed to target a concentrated prescriber base and enhance patient access. Beyond the US market, Citius Oncology has negotiated agreements with regional partners to enable access in parts of Europe and the Middle East through Named Patient Programs. The company is also exploring future labe
Show less
Read more
Impact Snapshot
Event Time:
CTXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTXR alerts
High impacting Citius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CTXR
News
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development ProgramPR Newswire
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ [Yahoo! Finance]Yahoo! Finance
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™PR Newswire
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePR Newswire
CTXR
Earnings
- 5/14/25 - Beat
CTXR
Sec Filings
- 3/4/26 - Form 8-K
- 2/24/26 - Form ARS
- 2/24/26 - Form DEFA14A
- CTXR's page on the SEC website